ClinicalTrials.gg
Status unknownNCT03774979Updated Nov 8, 2022

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

A Phase 1 interventional study of SHR-1701 in Solid Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 16 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
193
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Enrollment
131st of 401
193 · median 90
Started
2019
with 25 others
Phase 1
93 of 485
47 open now
Registered
123rd of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 131st largest by enrollment of the 401 interventional ones that give a count, is one of 26 that started in 2019, is one of 93 in phase 1, and was the 123rd registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety and tolerability of SHR-1701 at different dose levels. Study consists of dose-escalation part and an expansion part in subjects with metastatic or locally advanced solid tumors.

Read the detailed description

This is a Phase I, open-label, multiple-ascending dose trial. Study consists of dose-escalation part in subjects with metastatic or locally advanced solid tumors, and expansion part with selected indications.

03

Conditions studied

  • Solid Tumor

Browse trials for

Keywords

  • SHR-1701
  • Solid tumor
  • Metastatic or locally advanced solid tumors
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to provide signed form, and able to comply with all procedures.
  • or cytologically proven or locally advanced solid tumors.
  • Male or female subjects aged 18-75 years.
  • >= 12 weeks as judged by the Investigator.
  • (ECOG) performance status of 0 to 1 at trial entry.
  • Disease must be measurable with at least 1 uni dimensional by (RECIST) version 1.1.
  • Adequate hematological, hepatic and renal function as defined in the protocol

Other protocol-defined inclusion criteria could apply.

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with an anti-PD1, , anti-CTLA-4 or a TGFb inhibitor.
  • Anticancer treatment within 28 days before the first dose of study drug.
  • Major surgery within 28 days before start of trial treatment.
  • Systemic therapy with agents within 7 days prior to the first dose of study drug; or use any drug within 28 days before the start of trial treatment.
  • With any active disease or history of autoimmune disease.
  • With active central nervous system (CNS) causing clinical symptoms or requiring therapeutic intervention.
  • cardiovascular and cerebrovascular diseases
  • History of immunodeficiency including seropositive for (HIV), or other acquired or congenital immunedeficient disease, or any active systemic viral infection requiring therapy.
  • Previous malignant disease (other than the target to be investigated in the trial) within the last 2 years. Subjects with history of cervical carcinoma in situ, superficial or non-invasive bladder cancer or basal cell or squamous cell cancer in situ previously treated with curative intent are NOT excluded.
  • Receipt of any organ transplantation, including stem-cell transplantation

Other protocol-defined exclusion criteria could apply

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
193 participants (actual)

Study arms

  • Experimental
    SHR-1701

    intravenous infusion

    Drug: SHR-1701

Interventions

  • Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.

06

What researchers measure

Primary outcomes

  1. Dose escalation part: Safety and tolerability of SHR-1701 in advanced malignancies.

    Number of Subjects who occurs dose-limiting toxicity (DLTs).

    Time frame: Up to 3/4 weeks.

  2. Clinical expansion Part: Objective Response Rate(ORR)

    ORR is define as the percentage of participants in the analysis population who havea Complete Response(CR:Disappearance of all target lesions)or a Partial Response(PR :30% decrease in the sum of diameter of target lesions) per RECIST 1.1.

    Time frame: Up to 6 weeks

Secondary outcomes

  1. Clinical expansion Part: Safety of SHR-1701

    Number of subjects who occurs treatment-related Adverse Events(AEs)

    Time frame: Up to 4 weeks after last treatment

  2. Clinical expansion Part: Disease Control Rate(DCR) per RECIST1.1

    DCR is define as the percentage of participants in the analysis population who have a CR,PR or SD per RECIST 1.1.

    Time frame: Up to 6 weeks

  3. Clinical expansion Part: Duration of Response (DOR)per RECIST1.1

    DOR is define as the time from first documented evidence of CR or PR until disease progression per RECIST 1.1

    Time frame: Up to 6 weeks

  4. Clinical expansion Part:Progression-free survival(PFS) per RECIST1.1

    PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1

    Time frame: 12months (anticipated)

07

Study locations

16 sites
  • Anhui Chest Hospital-Departmen of Tumor Radiotherapy
    Hefei, Anhui, China
  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine-Cancer Center
    Guangzhou, Guangzhou, China
  • Xinxiang Central Hospital-Department of Respiratory Physicians
    Xinxiang, Henan, China
  • The First Affiliated Hospital of Zhengzhou University-Department of Medical Oncology
    Zhengzhou, Henan, China
  • Cancer Hospital of Hunan Province
    Changsha, Hunan, China
  • Hunan Cancer Hospital-Gynecologic Oncology
    Changsha, Hunan, China
  • Jangsu Cancer Hospital
    Nanjing, Jiangsu, China
  • The First Rffiurted Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • The First Affiliated Hospital Of Nanchang University
    Nanchang, Jiangxi 330006, China
  • The First Hospital of China Medical University-Department of Oncology
    Shenyang, Liaoning, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
    Hangzhou, Zhejiang, China
  • Beijing Chest Hospital,Capital Medical University-Integrated Department
    Beijing, China
  • Tumor Hospital of the Chinese Academy of Medical Sciences
    Beijing, China
  • ChongQing Cancer Hospital-gynecologic oncology
    Chongqing, China
  • Chongqing Cancer Hospital
    Chongqing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Mar 2023, 50 months after the start.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 50 months is close to that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2018
First posted
Dec 13, 2018
StartActual
Jan 24, 2019
Primary completionEst.
Mar 2023
CompletionEst.
Dec 2023
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03774979
Responsible party
Sponsor
First posted
Dec 13, 2018
Start date
Jan 24, 2019
Primary completion
Mar 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Nov 8, 2022

Study contacts

Jifeng Feng, MD
principal investigator · Jiangsu Cancer Institute & Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1701

Start the discussion